Trials / Completed
CompletedNCT01340456
Cholesterol Metabolites as Markers for CYP3A Induction
Induction of Drug Metabolism by Rifampicin to Compare the Endogenous Biomarker 4beta-OHcholesterol With the Probe Drug Midazolam as Quantitative Markers for Cytochrome P450 3A4 Induction
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Karolinska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objectives of this study are: * To investigate if the endogenous cholesterol metabolite, 4beta-OHcholesterol could be used as a marker for induction of cytochrome P450 (CYP) 3A4. * To compare 4beta-OHcholesterol with midazolam as a marker for induction of CYP3A4.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifampicin treatment | induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD) |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2011-04-22
- Last updated
- 2011-07-11
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT01340456. Inclusion in this directory is not an endorsement.